Manufacturer eyes potent compounds

Swiss pharmaceutical group Helsinn has announced plans to create a competitive manufacturing organization focused on highly potent compounds that includes both R&D and production capabilities. Financial investments and a new organization of manufacturing sites in Ireland and Switzerland are part of the strategy. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.